Exclusive Characteristics of the p.E555K Dominant-Negative Variant in Autosomal Dominant E47 Deficiency.


Journal

Journal of clinical immunology
ISSN: 1573-2592
Titre abrégé: J Clin Immunol
Pays: Netherlands
ID NLM: 8102137

Informations de publication

Date de publication:
29 Jul 2024
Historique:
received: 02 02 2024
accepted: 21 06 2024
medline: 29 7 2024
pubmed: 29 7 2024
entrez: 29 7 2024
Statut: epublish

Résumé

Transcription factor 3 (TCF3) encodes 2 transcription factors generated by alternative splicing, E12 and E47, which contribute to early lymphocyte differentiation. In humans, autosomal dominant (AD) E47 transcription factor deficiency is an inborn error of immunity characterized by B-cell deficiency and agammaglobulinemia. Only the recurrent de novo p.E555K pathogenic variant has been associated with this disease and acts via a dominant-negative (DN) mechanism. In this study, we describe the first Asian patient with agammaglobulinemia caused by the TCF3 p.E555K variant and provide insights into the structure and function of this variant. TCF3 variant was identified by inborn errors of immunity-related gene panel sequencing. The variant E555K was characterized by alanine scanning of the E47 basic region and comprehensive mutational analysis focused on position 555. The patient was a 25-year-old male with B-cell deficiency, agammaglobulinemia, and mild facial dysmorphic features. We confirmed the diagnosis of AD E47 transcription factor deficiency by identifying a heterozygous missense variant, c.1663 G>A; p.E555K, in TCF3. Alanine scanning of the E47 basic region revealed the structural importance of position 555. Comprehensive mutational analysis focused on position 555 showed that only the glutamate-to-lysine substitution had a strong DN effect. 3D modeling demonstrated that this variant not only abolished hydrogen bonds involved in protein‒DNA interactions, but also inverted the charge on the surface of the E47 protein. Our study reveals the causative mutation hotspot in the TCF3 DN variant and highlights the weak negative selection associated with the TCF3 gene.

Identifiants

pubmed: 39073655
doi: 10.1007/s10875-024-01758-x
pii: 10.1007/s10875-024-01758-x
doi:

Substances chimiques

TCF3 protein, human 0
Basic Helix-Loop-Helix Transcription Factors 0

Types de publication

Journal Article Case Reports

Langues

eng

Sous-ensembles de citation

IM

Pagination

167

Informations de copyright

© 2024. The Author(s).

Références

Murre C, McCaw PS, Baltimore D. A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins. Cell. 1989;56(5):777–83. https://doi.org/10.1016/0092-8674(89)90682-x .
doi: 10.1016/0092-8674(89)90682-x pubmed: 2493990
Sun XH, Baltimore D. An inhibitory domain of E12 transcription factor prevents DNA binding in E12 homodimers but not in E12 heterodimers. Cell. 1991;64(2):459–70. https://doi.org/10.1016/0092-8674(91)90653-g .
doi: 10.1016/0092-8674(91)90653-g pubmed: 1846322
Ephrussi A, Church GM, Tonegawa S, Gilbert W. B lineage-specific interactions of an immunoglobulin enhancer with cellular factors in vivo. Science. 1985;227(4683):134–40. https://doi.org/10.1126/science.3917574 .
doi: 10.1126/science.3917574 pubmed: 3917574
Church GM, Ephrussi A, Gilbert W, Tonegawa S. Cell-type-specific contacts to immunoglobulin enhancers in nuclei. Nature. 1985;313(6005):798–801. https://doi.org/10.1038/313798a0 .
doi: 10.1038/313798a0 pubmed: 3919308
Murre C, McCaw PS, Vaessin H, Caudy M, Jan LY, Jan YN, et al. Interactions between heterologous helix-loop-helix proteins generate complexes that bind specifically to a common DNA sequence. Cell. 1989;58(3):537–44. https://doi.org/10.1016/0092-8674(89)90434-0 .
doi: 10.1016/0092-8674(89)90434-0 pubmed: 2503252
Lassar AB, Davis RL, Wright WE, Kadesch T, Murre C, Voronova A, et al. Functional activity of myogenic HLH proteins requires hetero-oligomerization with E12/E47-like proteins in vivo. Cell. 1991;66(2):305–15. https://doi.org/10.1016/0092-8674(91)90620-e .
doi: 10.1016/0092-8674(91)90620-e pubmed: 1649701
Blackwell TK, Weintraub H. Differences and similarities in DNA-binding preferences of MyoD and E2A protein complexes revealed by binding site selection. Science. 1990;250(4984):1104–10. https://doi.org/10.1126/science.2174572 .
doi: 10.1126/science.2174572 pubmed: 2174572
Murre C, Bain G, van Dijk MA, Engel I, Furnari BA, Massari ME, et al. Structure and function of helix-loop-helix proteins. Biochim Biophys Acta. 1994;1218(2):129–35. https://doi.org/10.1016/0167-4781(94)90001-9 .
doi: 10.1016/0167-4781(94)90001-9 pubmed: 8018712
Lazorchak A, Jones ME, Zhuang Y. New insights into E-protein function in lymphocyte development. Trends Immunol. 2005;26(6):334–8. https://doi.org/10.1016/j.it.2005.03.011 .
doi: 10.1016/j.it.2005.03.011 pubmed: 15922950
Murre C, Voronova A, Baltimore D. B-cell- and myocyte-specific E2-box-binding factors contain E12/E47-like subunits. Mol Cell Biol. 1991;11(2):1156–60. https://doi.org/10.1128/mcb.11.2.1156-1160.1991 .
doi: 10.1128/mcb.11.2.1156-1160.1991 pubmed: 1990271 pmcid: 359799
Shen CP, Kadesch T. B-cell-specific DNA binding by an E47 homodimer. Mol Cell Biol. 1995;15(8):4518–24. https://doi.org/10.1128/mcb.15.8.4518 .
doi: 10.1128/mcb.15.8.4518 pubmed: 7623842 pmcid: 230691
Kee BL, Quong MW, Murre C. E2A proteins: essential regulators at multiple stages of B-cell development. Immunol Rev. 2000;175:138–49.
doi: 10.1111/j.1600-065X.2000.imr017514.x pubmed: 10933599
Bain G, Maandag EC, Izon DJ, Amsen D, Kruisbeek AM, Weintraub BC, et al. E2A proteins are required for proper B cell development and initiation of immunoglobulin gene rearrangements. Cell. 1994;79(5):885–92. https://doi.org/10.1016/0092-8674(94)90077-9 .
doi: 10.1016/0092-8674(94)90077-9 pubmed: 8001125
Zhuang Y, Cheng P, Weintraub H. B-lymphocyte development is regulated by the combined dosage of three basic helix-loop-helix genes, E2A, E2-2, and HEB. Mol Cell Biol. 1996;16(6):2898–905. https://doi.org/10.1128/mcb.16.6.2898 .
doi: 10.1128/mcb.16.6.2898 pubmed: 8649400 pmcid: 231283
Greenbaum S, Zhuang Y. Regulation of early lymphocyte development by E2A family proteins. Semin Immunol. 2002;14(6):405–14. https://doi.org/10.1016/s1044532302000751 .
doi: 10.1016/s1044532302000751 pubmed: 12457613
Murre C. Helix-loop-helix proteins and lymphocyte development. Nat Immunol. 2005;6(11):1079–86. https://doi.org/10.1038/ni1260 .
doi: 10.1038/ni1260 pubmed: 16239924
Beck K, Peak MM, Ota T, Nemazee D, Murre C. Distinct roles for E12 and E47 in B cell specification and the sequential rearrangement of immunoglobulin light chain loci. J Exp Med. 2009;206(10):2271–84. https://doi.org/10.1084/jem.20090756 .
doi: 10.1084/jem.20090756 pubmed: 19752184 pmcid: 2757879
Dobbs AK, Bosompem A, Coustan-Smith E, Tyerman G, Saulsbury FT, Conley ME. Agammaglobulinemia associated with BCR(-) B cells and enhanced expression of CD19. Blood. 2011;118(7):1828–37. https://doi.org/10.1182/blood-2011-01-330472 .
doi: 10.1182/blood-2011-01-330472 pubmed: 21693761 pmcid: 3158715
Boisson B, Wang YD, Bosompem A, Ma CS, Lim A, Kochetkov T, et al. A recurrent dominant negative E47 mutation causes agammaglobulinemia and BCR(-) B cells. J Clin Invest. 2013;123(11):4781–5. https://doi.org/10.1172/jci71927 .
doi: 10.1172/jci71927 pubmed: 24216514 pmcid: 3809807
Al Sheikh E, Arkwright PD, Herwadkar A, Hussell T, Briggs TA. TCF3 Dominant negative variant causes an early block in B-Lymphopoiesis and agammaglobulinemia. J Clin Immunol. 2021;41(6):1391–4. https://doi.org/10.1007/s10875-021-01049-9 .
doi: 10.1007/s10875-021-01049-9 pubmed: 33905048
Boast B, Goel S, Gonzalez-Granado LI, Niemela J, Stoddard J, Edwards ESJ, et al. TCF3 haploinsufficiency defined by immune, clinical, gene-dosage, and murine studies. J Allergy Clin Immunol. 2023;152(3):736–47. https://doi.org/10.1016/j.jaci.2023.05.017 .
doi: 10.1016/j.jaci.2023.05.017 pubmed: 37277074
Ben-Ali M, Yang J, Chan KW, Ben-Mustapha I, Mekki N, Benabdesselem C, et al. Homozygous transcription factor 3 gene (TCF3) mutation is associated with severe hypogammaglobulinemia and B-cell acute lymphoblastic leukemia. J Allergy Clin Immunol. 2017;140(4):1191–e44. https://doi.org/10.1016/j.jaci.2017.04.037 .
doi: 10.1016/j.jaci.2017.04.037 pubmed: 28532655
Qureshi S, Sheikh MDA, Qamar FN. Autosomal recessive agammaglobulinemia - first case with a novel TCF3 mutation from Pakistan. Clin Immunol. 2019;198:100–1. https://doi.org/10.1016/j.clim.2018.07.016 .
doi: 10.1016/j.clim.2018.07.016 pubmed: 30063982
Khoshnevisan R, Hassanzadeh S, Klein C, Rohlfs M, Grimbacher B, Molavi N, et al. B-cells absence in patients diagnosed as inborn errors of immunity: a registry-based study. Immunogenetics. 2024;76(3):189–202. https://doi.org/10.1007/s00251-024-01342-y .
doi: 10.1007/s00251-024-01342-y pubmed: 38683392
Ameratunga R, Koopmans W, Woon ST, Leung E, Lehnert K, Slade CA, et al. Epistatic interactions between mutations of TACI (TNFRSF13B) and TCF3 result in a severe primary immunodeficiency disorder and systemic lupus erythematosus. Clin Transl Immunol. 2017;6(10):e159. https://doi.org/10.1038/cti.2017.41 .
doi: 10.1038/cti.2017.41
Tangye SG, Al-Herz W, Bousfiha A, Cunningham-Rundles C, Franco JL, Holland SM, et al. Human inborn errors of immunity: 2022 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2022;42(7):1473–507. https://doi.org/10.1007/s10875-022-01289-3 .
doi: 10.1007/s10875-022-01289-3 pubmed: 35748970 pmcid: 9244088
Picard C, Bobby Gaspar H, Al-Herz W, Bousfiha A, Casanova JL, Chatila T, et al. International Union of Immunological Societies: 2017 primary immunodeficiency diseases Committee Report on Inborn errors of immunity. J Clin Immunol. 2018;38(1):96–128. https://doi.org/10.1007/s10875-017-0464-9 .
doi: 10.1007/s10875-017-0464-9 pubmed: 29226302
Bousfiha A, Jeddane L, Picard C, Ailal F, Bobby Gaspar H, Al-Herz W, et al. The 2017 IUIS phenotypic classification for primary immunodeficiencies. J Clin Immunol. 2018;38(1):129–43. https://doi.org/10.1007/s10875-017-0465-8 .
doi: 10.1007/s10875-017-0465-8 pubmed: 29226301
El Omari K, Hoosdally SJ, Tuladhar K, Karia D, Hall-Ponsele E, Platonova O, et al. Structural basis for LMO2-driven recruitment of the SCL:E47bHLH heterodimer to hematopoietic-specific transcriptional targets. Cell Rep. 2013;4(1):135–47. https://doi.org/10.1016/j.celrep.2013.06.008 .
doi: 10.1016/j.celrep.2013.06.008 pubmed: 23831025 pmcid: 3714592
Takashima T, Okamura M, Yeh TW, Okano T, Yamashita M, Tanaka K, et al. Multicolor Flow Cytometry for the diagnosis of primary Immunodeficiency diseases. J Clin Immunol. 2017;37(5):486–95. https://doi.org/10.1007/s10875-017-0405-7 .
doi: 10.1007/s10875-017-0405-7 pubmed: 28597144
Tadaka S, Kawashima J, Hishinuma E, Saito S, Okamura Y, Otsuki A, et al. jMorp: Japanese multi-omics reference panel update report 2023. Nucleic Acids Res. 2024;52(D1):D622–32. https://doi.org/10.1093/nar/gkad978 .
doi: 10.1093/nar/gkad978 pubmed: 37930845
Cunningham BC, Wells JA. High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis. Science. 1989;244(4908):1081–5. https://doi.org/10.1126/science.2471267 .
doi: 10.1126/science.2471267 pubmed: 2471267
Kagawa R, Fujiki R, Tsumura M, Sakata S, Nishimura S, Itan Y, et al. Alanine-scanning mutagenesis of human signal transducer and activator of transcription 1 to estimate loss- or gain-of-function variants. J Allergy Clin Immunol. 2017;140(1):232–41. https://doi.org/10.1016/j.jaci.2016.09.035 .
doi: 10.1016/j.jaci.2016.09.035 pubmed: 28011069
Voronova A, Baltimore D. Mutations that disrupt DNA binding and dimer formation in the E47 helix-loop-helix protein map to distinct domains. Proc Natl Acad Sci U S A. 1990;87(12):4722–6. https://doi.org/10.1073/pnas.87.12.4722 .
doi: 10.1073/pnas.87.12.4722 pubmed: 2112746 pmcid: 54189
Ellenberger T, Fass D, Arnaud M, Harrison SC. Crystal structure of transcription factor E47: E-box recognition by a basic region helix-loop-helix dimer. Genes Dev. 1994;8(8):970–80. https://doi.org/10.1101/gad.8.8.970 .
doi: 10.1101/gad.8.8.970 pubmed: 7926781
Maerkl SJ, Quake SR. Experimental determination of the evolvability of a transcription factor. Proc Natl Acad Sci U S A. 2009;106(44):18650–5. https://doi.org/10.1073/pnas.0907688106 .
doi: 10.1073/pnas.0907688106 pubmed: 19841254 pmcid: 2765923
De Masi F, Grove CA, Vedenko A, Alibes A, Gisselbrecht SS, Serrano L, et al. Using a structural and logics systems approach to infer bHLH-DNA binding specificity determinants. Nucleic Acids Res. 2011;39(11):4553–63. https://doi.org/10.1093/nar/gkr070 .
doi: 10.1093/nar/gkr070 pubmed: 21335608 pmcid: 3113581
O’Shea EK, Rutkowski R, Kim PS. Mechanism of specificity in the Fos-Jun oncoprotein heterodimer. Cell. 1992;68(4):699–708. https://doi.org/10.1016/0092-8674(92)90145-3 .
doi: 10.1016/0092-8674(92)90145-3 pubmed: 1739975
O’Shea EK, Lumb KJ, Kim PS. Peptide ‘Velcro’: design of a heterodimeric coiled coil. Curr Biol. 1993;3(10):658–67. https://doi.org/10.1016/0960-9822(93)90063-t .
doi: 10.1016/0960-9822(93)90063-t pubmed: 15335856
Nohaile MJ, Hendsch ZS, Tidor B, Sauer RT. Altering dimerization specificity by changes in surface electrostatics. Proc Natl Acad Sci U S A. 2001;98(6):3109–14. https://doi.org/10.1073/pnas.051624498 .
doi: 10.1073/pnas.051624498 pubmed: 11248040 pmcid: 30615
Escherich C, Chen W, Miyamoto S, Namikawa Y, Yang W, Teachey DT, et al. Identification of TCF3 germline variants in pediatric B-cell acute lymphoblastic leukemia. Blood Adv. 2023;7(10):2177–80. https://doi.org/10.1182/bloodadvances.2022008563 .
doi: 10.1182/bloodadvances.2022008563 pubmed: 36576946
Rapaport F, Boisson B, Gregor A, Beziat V, Boisson-Dupuis S, Bustamante J, et al. Negative selection on human genes underlying inborn errors depends on disease outcome and both the mode and mechanism of inheritance. Proc Natl Acad Sci U S A. 2021;118(3). https://doi.org/10.1073/pnas.2001248118 .
Gussow AB, Petrovski S, Wang Q, Allen AS, Goldstein DB. The intolerance to functional genetic variation of protein domains predicts the localization of pathogenic mutations within genes. Genome Biol. 2016;17:9. https://doi.org/10.1186/s13059-016-0869-4 .
doi: 10.1186/s13059-016-0869-4 pubmed: 26781712 pmcid: 4717634
Brandes N, Goldman G, Wang CH, Ye CJ, Ntranos V. Genome-wide prediction of disease variant effects with a deep protein language model. Nat Genet. 2023;55(9):1512–22. https://doi.org/10.1038/s41588-023-01465-0 .
doi: 10.1038/s41588-023-01465-0 pubmed: 37563329 pmcid: 10484790

Auteurs

Takanori Utsumi (T)

Department of Pediatrics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.

Miyuki Tsumura (M)

Department of Pediatrics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.

Masato Yashiro (M)

Department of Pediatrics, Okayama University Hospital, Okayama, Japan.

Zenichiro Kato (Z)

Department of Pediatrics, Graduate School of Medicine, Gifu University, Gifu, Japan.
Structural Medicine, United Graduate School of Drug Discovery and Medical Information Science, Gifu University, Gifu, Japan.

Kosuke Noma (K)

Department of Pediatrics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.

Fumiaki Sakura (F)

Department of Pediatrics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Department of Applied Genomics, Kazusa DNA Research Institute, Chiba, Japan.

Reiko Kagawa (R)

Department of Pediatrics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.

Yoko Mizoguchi (Y)

Department of Pediatrics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.

Shuhei Karakawa (S)

Department of Pediatrics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.

Hidenori Ohnishi (H)

Department of Pediatrics, Graduate School of Medicine, Gifu University, Gifu, Japan.

Charlotte Cunningham-Rundles (C)

Division of Allergy and Clinical Immunology, Departments of Medicine and Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Peter D Arkwright (PD)

Lydia Becker Institute of Immunology and Inflammation, University of Manchester, Manchester, UK.

Masao Kobayashi (M)

Japanese Red Cross Chugoku-Shikoku Block Blood Center, Hiroshima, Japan.

Hirokazu Kanegane (H)

Department of Child Health and Development, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.

Dusan Bogunovic (D)

Center for Inborn Errors of Immunity, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Bertrand Boisson (B)

St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA.
Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.
Paris Descartes University, Imagine Institute, Paris, France.

Jean-Laurent Casanova (JL)

St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA.
Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.
Paris Descartes University, Imagine Institute, Paris, France.
Pediatric Hematology-Immunology Unit, Necker Hospital for Sick Children, AP-HP, Paris, France.
Howard Hughes Medical Institute (HHMI), New York, NY, USA.

Takaki Asano (T)

Department of Pediatrics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. tasano02@hiroshima-u.ac.jp.
Department of Genetics and Cell Biology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan. tasano02@hiroshima-u.ac.jp.

Satoshi Okada (S)

Department of Pediatrics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. sokada@hiroshima-u.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH